Drug intelligence / Profile preview

doxycycline + hydroxychloroquine + leflunomide + tofacitinib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy consisting of four medications used for the treatment of rheumatoid arthritis (RA). The combination includes doxycycline (an antibiotic), hydroxychloroquine (an antimalarial), leflunomide (a disease-modifying antirheumatic drug/DMARD), and tofacitinib (an oral Janus kinase inhibitor). This combination represents a multi-targeted approach to treating RA, with each component working through different mechanisms to reduce inflammation and disease activity.

Targets

JAK3 (Janus kinase 3)JAK2 (Janus kinase 2)TLR9 (Toll-like receptor 9)MMP12 (Macrophage Metalloelastase)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on doxycycline + hydroxychloroquine + leflunomide + tofacitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxycycline + hydroxychloroquine + leflunomide + tofacitinib.

Explore the full profile